# A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches

> **NCT02160067** · PHASE1 · COMPLETED · sponsor: **Mundipharma Research Limited** · enrollment: 20 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Second generation BTDS patch
- **DRUG:** First generation BuTrans patch

## Key facts

- **NCT ID:** NCT02160067
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02160067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02160067, "A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02160067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*